TNGX
Tango Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.63B
P/E Ratio
—
EPS
$-0.87
Beta
1.31
52W High
$28.41
52W Low
$1.03
50-Day MA
$18.94
200-Day MA
$11.19
Dividend Yield
—
Profit Margin
-162.90%
Forward P/E
—
PEG Ratio
—
About Tango Therapeutics Inc
Tango Therapeutics Inc. is a clinical-stage biotechnology firm focused on revolutionizing cancer treatment through targeted therapies based on the principle of synthetic lethality. With a robust and diverse pipeline of innovative drug candidates, the company is poised to make significant strides in precision oncology. Tango is committed to enhancing its research capabilities through strategic partnerships with esteemed academic institutions, further solidifying its role as a leader in advancing treatment paradigms in oncology. Through its visionary approach, Tango aims to address critical unmet needs in cancer care and significantly improve patient outcomes.
Fundamentals
| Revenue (TTM) | $62.38M |
| Gross Profit (TTM) | $-69.78M |
| EBITDA | $-109.01M |
| Operating Margin | -178.40% |
| Return on Equity | -37.20% |
| Return on Assets | -19.50% |
| Revenue/Share (TTM) | $0.54 |
| Book Value | $2.55 |
| Price-to-Book | 10.48 |
| Price-to-Sales (TTM) | 58.13 |
| EV/Revenue | 53.17 |
| EV/EBITDA | -0.91 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $144.24M |
| Float | $68.44M |
| % Insiders | 1.38% |
| % Institutions | 119.87% |
Historical Volatility
HV 10-Day
63.25%
HV 20-Day
76.37%
HV 30-Day
69.99%
HV 60-Day
87.23%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($23.90 target)
1
Strong Buy9
Buy1
HoldData last updated: 4/29/2026